上 市 公 司 2025 年 08 月 26 日 比依股份 (603215) ——2025 年中报点评：Q2 业绩符合预期，新品类持续 放量 报告原因：有业绩公布需要点评 增持（维持） | 市场数据： | 2025 年 08 月 25 日 | | --- | --- | | 收盘价（元） | 21.52 | | 一年内最高/最低（元） | 23.60/12.21 | | 市净率 | 3.4 | | 股息率%（分红/股价） | 1.39 | | 流通 A 股市值（百万元） | 4,029 | | 上证指数/深证成指 | 3,883.56/12,441.07 | | 注："股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 06 月 30 日 | | --- | --- | | 每股净资产（元） | 6.27 | | 资产负债率% | 61.52 | | 总股本/流通 A 股（百万） | 188/187 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： 家用电器 08-26 09-26 10-26 11-26 12-26 01-26 02-26 03-26 ...

开源证券股份有限公司余汝意,聂媛媛近期对毕得医药进行研究并发布了研究报告《公司信息更新报告： 2025H1业绩超预期增长，科学试剂业务表现亮眼》，给予毕得医药买入评级。 毕得医药(688073) 公司2025H1业绩超预期，上半年收入利润持续加速增长 2025H1，公司实现营业收入6.28亿元，同比增长17.91%；归母净利润0.73亿元，同比增长41.60%；扣非归 母净利润0.59亿元，同比增长22.60%。若剔除股份支付影响，2025H1公司净利润为0.90亿元，同比增长 70.60%。单看2025Q2，公司实现营业收入3.31亿元，同比增长22.86%；归母净利润0.43亿元，同比增长 65.78%；扣非归母净利润0.31亿元，同比增长36.20%。公司2025年上半年业绩表现亮眼，收入与利润均实 现持续加速增长。我们看好公司长期发展，维持公司2025-2027年盈利预测，预计归母净利润分别为 1.42/2.02/2.56亿元，EPS为1.56/2.22/2.82元，当前股价对应P/E分别为41.3/29.0/22.9倍，维持"买入"评级。 科学试剂业务表现亮眼，海外业务贡献提升 分业务看，2025H ...

Investment Rating - The investment rating for the company is maintained at "Buy" with a target price of RMB 17.90 [1][5]. Core Insights - The company reported a revenue of RMB 2.96 billion for 1H25, representing a year-over-year increase of 6.1%, and a net profit attributable to shareholders of RMB 467 million, up 7.0% year-over-year [1]. - The growth was driven by the consumer goods testing and trade assurance segments, while the pharmaceutical and medical sectors are expected to recover [2]. - The company is accelerating its internationalization through acquisitions, which is expected to enhance its capabilities in ESG, food, and dual-carbon testing [4]. Revenue and Profitability - In 1H25, the company achieved a revenue of RMB 2.96 billion, with Q2 revenue reaching RMB 1.67 billion, a year-over-year increase of 4.6% and a quarter-over-quarter increase of 30% [1]. - The net profit margin for Q2 25 improved to 19.79%, benefiting from a reduction in credit impairment losses [3]. - The company is expected to maintain a compound annual growth rate (CAGR) of 11% in net profit from 2025 to 2027, with projected net profits of RMB 1.06 billion, RMB 1.16 billion, and RMB 1.26 billion for 2025, 2026, and 2027 respectively [5][11]. Segment Performance - The life sciences segment saw a revenue increase of 1.1% year-over-year to RMB 1.27 billion, while the industrial testing segment grew by 7.5% to RMB 600 million [2]. - The consumer goods testing segment reported a revenue increase of 13.2% to RMB 520 million, and the trade assurance segment grew by 13.5% to RMB 430 million [2]. - The pharmaceutical and medical segment's revenue increased by 1.3% to RMB 140 million, with expectations for recovery in demand [2]. International Expansion - The company completed the acquisition of Auspec Analysis and Testing, expanding into the geochemical testing field [4]. - Three additional acquisitions are anticipated in 2H25 to enhance international capabilities in social responsibility audits and food safety testing [4]. Valuation and Forecast - The company’s 2026 estimated PE ratio is projected at 26x, with a target price adjustment to RMB 17.90 based on this valuation [5][20]. - The company’s return on equity (ROE) is expected to remain significantly above the median of comparable companies [5].

丨证券研究报告丨 公司研究丨点评报告丨科沃斯（603486.SH） [Table_Title] 产品力提升优质增长，效率优化盈利改善 报告要点 [Table_Summary] 公司发布 2025 年半年报，2025 年上半年公司实现营业收入 86.76 亿元，同比+24.37%，实现 归母净利润 9.79 亿元，同比+60.84%，实现扣非归母净利润 8.60 亿元，同比+54.34%；对应 单二季度公司实现营业收入 48.18 亿元，同比+37.58%，实现归母净利润 5.05 亿元，同比 +62.19%，实现扣非归母净利润 5.04 亿元，同比+86.25%。 分析师及联系人 [Table_Author] 陈亮 SAC：S0490517070017 SFC：BUW408 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 科沃斯（603486.SH） cjzqdt11111 [Table_Title2] 产品力提升优质增长，效率优化盈利改善 [Table_Summary2] 事件描述 公司发布 2025 年半年报，2025 年上半年公司实现营业收入 86.76 ...

Group 1 - The core viewpoint is that the small home appliance industry is expected to continue its recovery trend this year, driven by the old-for-new home appliance policy and a low base effect [1][2] - The demand for small home appliances is showing a mild recovery, with the industry experiencing reduced competition and companies focusing on high-quality development, leading to further price recovery [2] - The profitability of small home appliance companies is anticipated to improve significantly due to the combination of demand recovery, alleviated price wars, and reduced costs from platform fee reductions [2] Group 2 - The small home appliance industry had steady growth before 2020, with a CAGR of 7% in online retail sales from 2016 to 2019, but faced challenges during the pandemic [2] - The industry is expected to see a recovery in demand in 4Q24 and 1Q25, with online retail sales projected to increase by 8% and 6% year-on-year, respectively, primarily driven by price increases [2] - Companies are focusing on improving profitability through strategies such as market penetration, product development, market expansion, and diversification [3]

Core Insights - Sea's Q1 2025 revenue increased by 29.6% year-over-year to $4.84 billion, slightly below analyst expectations of $4.89 billion [1] - The company reported a net profit of $411 million, a significant turnaround from a net loss of $23 million in the same period last year [1] - Adjusted EBITDA reached $946.5 million, marking a 136% year-over-year increase, indicating substantial improvement in profitability [1] E-commerce Segment - E-commerce revenue was $3.524 billion, up 28.3% year-over-year, with Gross Merchandise Value (GMV) at $28.6 billion, reflecting a 21.5% increase [1] - E-commerce accounted for 72.8% of total revenue, with core market revenue (including transaction and advertising fees) growing by 39.2% to $2.4 billion [1][2] - Value-added services revenue, including logistics, grew by 4.1% to $752 million [1] Digital Financial Services - Digital financial services contributed 16.3% to total revenue, driven primarily by growth in consumer and SME credit businesses, with revenue increasing by 57.6% to $787 million [1][2] - The segment's adjusted EBITDA contribution was $241 million, a 62.4% increase year-over-year [2] Digital Entertainment - Digital entertainment revenue was $496 million, up 8.2% year-over-year, with bookings reaching $775 million, a 51.4% increase [1] - This segment accounted for 10.2% of total revenue, with adjusted EBITDA contribution of $458 million, reflecting a 56.8% year-over-year growth [2] User Metrics - The company reported 661.8 million quarterly active users, an 11.3% increase year-over-year, and 64.6 million paying users, up 32.2% [2] Cost Structure - Total costs for the quarter were $2.605 billion, a 19.5% increase year-over-year, with specific costs for e-commerce, digital financial services, and digital entertainment reported as $1.934 billion, $106 million, and $181 million respectively [2] - Sales and marketing expenses totaled $930 million, up 20.8% year-over-year, with notable increases in digital financial services and digital entertainment marketing costs [2] Market Reaction - Following the earnings report, Sea's stock surged over 13% in pre-market trading, with a current market capitalization of $90.6 billion [3]

Core Viewpoint - The company, Tianji Technology, is facing challenges in profitability due to rapid technological updates in the industry, intense competition in the IT data center operation and maintenance market, and rising labor costs. The company is actively working on improving its competitive advantages and expanding its market presence, particularly in underrepresented regions. Group 1: Financial Performance - In Q1 2025, the company's main revenue reached 143 million yuan, a year-on-year increase of 136.35% [3] - The net profit attributable to shareholders was 3.25 million yuan, a year-on-year decrease of 1.62% [3] - The non-recurring net profit was 1.69 million yuan, a year-on-year increase of 112.37% [3] - The company's debt ratio stood at 19.71%, with investment income at -1.08 million yuan and financial expenses at -157,300 yuan [3] - The gross profit margin was reported at 24.45% [3] Group 2: Market Strategy and Competition - The company acknowledges the intense competition in the IT operation and maintenance market and is focused on tracking technological advancements and optimizing its R&D and service teams [2][3] - The company plans to strengthen its market presence in lower-revenue regions while maintaining its leading position in the East China region [2] Group 3: Cost Control Measures - The company is continuously optimizing R&D and service efficiency, enhancing performance evaluations, and refining its compensation system to control costs [3]

Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5][12]. Core Insights - The company reported a revenue of 2.678 billion RMB in 2024, a decrease of 1.46% year-on-year, and a net profit attributable to shareholders of -102 million RMB [2]. - In Q1 2025, the company achieved a revenue of 742 million RMB, reflecting a year-on-year increase of 9.82%, with a net profit of 27 million RMB, up 61.18% year-on-year [2]. - The company is focusing on the iterative development of refractive surgery techniques and has seen stable growth in essential projects [3]. Summary by Sections Performance Review - In 2024, the company generated revenue of 2.678 billion RMB, down 1.46% year-on-year, and reported a net loss of 102 million RMB [2]. - For Q1 2025, the company recorded revenue of 742 million RMB, a 9.82% increase year-on-year, with a net profit of 27 million RMB, marking a 61.18% increase year-on-year [2]. Operational Analysis - The refractive surgery segment generated 1.227 billion RMB in revenue in 2024, down 5.31% year-on-year, with a gross margin of 47.02% [3]. - The cataract project revenue was 576 million RMB, down 3.04% year-on-year, influenced by national procurement policies [3]. - The company is introducing new technologies to enhance its competitive edge and is focusing on high-end products to mitigate the impact of price reductions [3]. Expansion Strategy - The company is implementing a "national chain + local integration" strategy, focusing on urban centers and gradually maturing new hospitals to drive future growth [4]. Profitability Forecast - The company is expected to achieve net profits of 130 million RMB, 161 million RMB, and 202 million RMB for 2025, 2026, and 2027, respectively, with corresponding EPS of 0.87, 1.07, and 1.35 RMB [5].